Sucampo Pharmaceuticals, Inc. Release: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation

Published: Oct 08, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BETHESDA, Md., Oct. 8, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced clinical data showing that lubiprostone is efficacious and well tolerated in children and adolescents with functional constipation. The results were published in the Journal of Pediatric Gastroenterology & Nutrition.

Help employers find you! Check out all the jobs and post your resume.

Back to news